Trial Profile
Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Stroke; Transient ischaemic attacks
- Focus Adverse reactions
- Acronyms ETNA-AF-Hong Kong
- Sponsors Daiichi Sankyo Company
- 17 Aug 2022 Status changed from active, no longer recruiting to completed.
- 27 Jul 2021 Planned End Date changed from 8 Jul 2022 to 1 Jun 2022.
- 27 Jul 2021 Planned primary completion date changed from 8 Jul 2022 to 1 Jun 2022.